🇺🇸 KN046 in United States
3 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 3
Most-reported reactions
- Dysphagia — 1 report (33.33%)
- Performance Status Decreased — 1 report (33.33%)
- White Blood Cell Count Decreased — 1 report (33.33%)
Other Oncology approved in United States
Frequently asked questions
Is KN046 approved in United States?
KN046 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for KN046 in United States?
Jiangsu Alphamab Biopharmaceuticals Co., Ltd is the originator. The local marketing authorisation holder may differ — check the official source linked above.